Medicine Atlas

How Healing Is Practiced
Sign In
Text size
100%
Theme
Discovery

Discovery of Chemotherapeutic Drugs

Bacteriological and Antimicrobial Discovery

In 1909 Paul Ehrlich and his laboratory identified Compound 606, later named arsphenamine and marketed as Salvarsan, an arsenic based agent effective against the spirochete bacteria that cause syphilis. It was the first agent whose therapeutic effect had been predicted and pursued from theoretical chemical reasoning rather than found by accident, and Ehrlich described the goal of a drug that would strike a specific pathogen as a magic bullet. Salvarsan became the most widely used treatment for syphilis until penicillin replaced it in the 1940s, and the systematic search it represented gave the emerging field of chemotherapy its name.

Facts
Discovery YearSourced to the subject's own account
1909 1
DiscovererSourced to the subject's own account
Paul Ehrlich and Sahachiro Hata 1
Classification
Type/ClassificationSourced to the subject's own account
Drug Discovery 1
Connections

Associated With

Syphilis, Conditions

Compound 606, marketed as Salvarsan, was an arsenic based agent effective against the spirochete bacteria that cause syphilis.

Discovered By

Paul Ehrlich, Healers
Sources
1. Paul Ehrlich (Wikipedia)
Wikipedia
  • Biography, 1909 Compound 606 discovery
    With the support of his assistant Sahachiro Hata Ehrlich discovered in 1909 that Compound 606, Arsphenamine, effectively combatted "spirillum" spirochaetes bacteria, one of whose subspecies causes syphilis.
  • entity description, Discovery of Chemotherapeutic Drugs
    In 1909 Paul Ehrlich and his laboratory identified Compound 606, later named arsphenamine and marketed as Salvarsan, an arsenic based agent effective against the spirochete bacteria that cause syphilis.
View the Source
Comments (0)
No comments yet. Be the first to share a thought.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.